Abstract:To develop a new interventional oncology technique, "radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus thymidine kinase (GFP/HSV-TK)/ganciclovir (GCV) gene therapy of cholangiocarcinoma." Luciferase/mCherry-labeled cholangiocarcinoma cells and 24 mice with subcutaneously implanted cholangiocarcinoma cells were treated by: (i) a combination of green fluorescent protein (GFP)/HSV-TK/plasmid gene transfection followed by RFH and ganciclovir exposure; (ii) gene therapy alone; (iii) RFH alone; and (iv) phosphate-buffered saline (PBS) to serve as a control (6 mice per group). Cell viabilities were quantified by MTS assay. Bioluminescent optical imaging and transcutaneous ultrasound imaging were used to follow up the tumor growth over 2 weeks. For in-vivo technical validation of the new technique, pigs in two groups received either intrabiliary delivery of GFP/HSV-TK/plasmid using a needle-integrated balloon catheter flowed by RFH enhancement (n = 6) or gene delivery only (n = 6). GFP signal in bile duct walls were quantified by optical imaging.The non- parametric Mann-Whitney U test was used for statistical comparison of variables. MTS assay demonstrated the lowest cell proliferation in combination therapy compared with three control groups (24.0 ± 5.3% vs 41.9 ± 6.4% vs 72.0 ± 9.0% vs 100%, p<0.001). GFP optical imaging confirmed that GFP/HSV-TK gene expression peaked at day 2 after gene transfection. Bioluminescent optical imaging demonstrated the decreased bioluminescence signals in tumors of combination therapy, compared with other control groups (0.71 ± 0.16 vs 1.46 ± 0.21 vs 2.10 ± 0.27 vs 2.36 ± 0.28, p<0.001). Ultrasound imaging showed the smallest tumor volumes of the combination therapy group, compared with other groups (0.90 ± 0.21 VS 1.61 ± 0.21 VS 2.22 ± 0.25 VS 2.50 ± 0.30, p<0.001). optical imaging confirmed higher GFP expression in the bile ducts with RFH enhancement (signal to noise ratio: 1.28 ± 0.61 VS 0.49 ± 0.31, P<0.05). It is feasible to use intratumoral RFH to enhance GFP/HSV-TK/plasmid gene expression and HSV-TK/GCV gene therapy of cholangiocarcinomas.This concept may pave a new avenue for managing pancreatobiliary malignancies.(supported by an NIH RO1EBO12467)

[Antitumor Effects of Radioiodine Labeled KH901 on Nude Mice Bearing Hepatoma].

Inhibitory effect 131I-antiAFP McAb-DOX-BSA nanoparticles on hepatocellular carcinoma bearing nude mice

Enhanced Tumor Inhibiting Effect of 131I-Bdi-1-based Radioimmunotherapy and Cytosine Deaminase Gene Therapy Modulated by a Radio-Sensitive Promoter in Nude Mice Bearing Bladder Cancer

[Tumor-selective replication, cytotoxicity and GM-CSF production of oncolytic recombinant adenovirus in KH901 injection]

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

The Combined Antitumor Effects of 125I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model

Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene

Intrabiliary Radiofrequency Heating-Enhanced Direct Intratumoral GFP/HSV-TK Gene Therapy of Cholangiocarcinoma: A Preclinical Study on Mice and Pigs

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

[Experimental Study of Radioimmunotherapy for Xenograft of Human Esophageal Carcinoma].

Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.

Radioimmunoimaging of human hepatocellular carcinoma xenografts with 131I-anti-HBx monoclonal antibody

Phase I Clinical Trial of Targeted Therapy Using 131I-Hepama-1 Mab in Patients with Hepatocellular Carcinoma

Radioimmunotherapy for Hepatocellular Carcinoma (HCC) Using 131I-Anti HCC Isoferritin IgG: Preliminary Results of Experimental and Clinical Studies

Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy

EXPERIMENTAL STUDY OF INTRATUMOR INJECTION WITH GELATIN MICROSPHERES CONTAINING 131 I AND MITOMYCIN C IN IMPLANTED HEPATOMA-22 IN MICE

131I-c(RGD) 2 Combined Lentiviral Vector E8-codA-GFP in Treatment of Human Glioblastoma in Nude Mice

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer

Experimental Study of Intratumor Injection of 90Y-Sag for the Treatment of Liver Cancer in Mice

[Use of 99Mtc-Survivin Antisense Oligonucleotide in Diagnosis of Hepatocellular Carcinoma: an Experiment with Mice].